{
  "scenario_id": "pharma_personalized_medicine_2025",
  "context": "Global pharmaceutical company, 12,000 employees, $15B annual revenue, implementing personalized medicine platform for oncology and immunology therapeutic areas",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": ["CEO", "Chief Medical Officer", "CFO", "Board of Directors"],
    "influencers": ["VP Research & Development", "VP Commercial Operations", "Chief Data Officer", "Data Privacy Officer", "VP Regulatory Affairs", "Head of Digital Health"]
  },
  "request": {
    "amount": "$220,000,000",
    "purpose": "Build integrated personalized medicine platform combining genomic sequencing, AI-driven drug response prediction, and companion diagnostic development",
    "urgency": "high",
    "justification": "Capitalize on $150B precision medicine market opportunity with projected 35% improvement in clinical trial success rates and 40% faster time-to-market for targeted therapies"
  },
  "decision_process": [
    {
      "stage": "strategic_alignment",
      "duration": "6 weeks",
      "activities": ["Market opportunity analysis", "Competitive landscape assessment", "Internal capability gap analysis", "Strategic priority alignment"],
      "outcome": "Approved as core strategic initiative with board-level sponsorship"
    },
    {
      "stage": "technology_partnerships",
      "duration": "8 weeks",
      "activities": ["Genomic sequencing platform evaluation", "AI/ML vendor selection", "Data integration architecture design", "Partnership agreement negotiations"],
      "outcome": "Strategic partnerships secured with Illumina, Tempus AI, and Flatiron Health"
    },
    {
      "stage": "regulatory_strategy",
      "duration": "10 weeks",
      "activities": ["FDA breakthrough therapy pathway analysis", "Companion diagnostic regulatory framework", "Data privacy compliance assessment", "International regulatory alignment"],
      "outcome": "Regulatory strategy developed with FDA breakthrough designation pathway"
    },
    {
      "stage": "pilot_validation",
      "duration": "16 weeks",
      "activities": ["Oncology pilot trial design", "Patient cohort identification", "Data collection and analysis protocols", "Clinical outcome validation"],
      "outcome": "Pilot demonstrated 45% improvement in treatment response prediction accuracy"
    },
    {
      "stage": "platform_development",
      "duration": "24 weeks",
      "activities": ["Platform architecture implementation", "AI model training and validation", "Integration with existing clinical systems", "Security and compliance testing"],
      "outcome": "Scalable platform developed with SOC 2 Type II compliance"
    },
    {
      "stage": "commercial_launch",
      "duration": "12 weeks",
      "activities": ["Go-to-market strategy development", "Pricing model design", "Sales team training", "Market launch execution"],
      "outcome": "Platform launched with 15 initial pharmaceutical partners"
    }
  ],
  "business_impact": {
    "expected_revenue": "$750,000,000",
    "projected_market_entry": "36 months",
    "risk_factors": ["Evolving regulatory landscape for genomic data", "Data privacy and consent challenges", "Technology integration complexity", "Market adoption slower than projected", "Competition from specialized biotech firms"],
    "strategic_benefits": ["Leadership position in precision medicine", "Accelerated drug development pipeline", "New revenue streams from companion diagnostics", "Enhanced clinical trial efficiency", "Improved patient outcomes and market differentiation"]
  }
}